Recently added
This page was added on 04 June 2018.
Updates made
This page was updated on [date-counter-updated-date]. View history of updates
Sponsor
Pfizer Australia
Administration route
Intramuscular injection
Vaccine group
Pneumococcal conjugate vaccines
Description:
Registered for use in children aged ≥6 weeks and in adults.
13vPCV — 13-valent pneumococcal conjugate vaccine
Each 0.5 mL monodose pre-filled syringe contains:
- 2.2 µg each of pneumococcal capsular polysaccharide of serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F
- 4.4 µg of pneumococcal capsular polysaccharide of serotype 6B
- succinic acid
- polysorbate 80
Antigens are conjugated to non-toxic Corynebacterium diphtheriae CRM197 protein and adsorbed onto 0.565 mg aluminium phosphate.
For Product Information and Consumer Medicine Information about Prevenar 13 visit the Therapeutic Goods Administration website.
Additional vaccine information
For detailed advice on vaccine dosage, administration, contraindications and precautions, and variations from product information, please visit the relevant disease chapter/s.
Related diseases
Page history
Last updated
Last reviewed